ElizabethAmyMorganMD

Hematopathology, Anatomic Pathology, Clinical Pathology

Assistant Professor, Harvard Medical School; Associate Pathologist, Brigham and Women's Hospital; Residency Program Director, Pathology Training Program, Brigham and Women's Hospital

Join to view full profile

Dr. Morgan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Morgan's full profile

Already have an account?

Office
75 Francis St.
Dept Of Pathology At Bwh
Boston, MA 02115
Phone+1 617-732-7510

Education & Training

Brigham and Women's HospitalFellowship, Hematopathology, 2011 - 2012
Brigham and Women's HospitalResidency, Pathology-Anatomic and Clinical, 2007 - 2011
Washington University in St. Louis School of MedicineClass of 2007

Certifications & Licensure

MA State Medical License 2010 - 2025
American Board of Pathology Pathology - Anatomic/Pathology - Clinical
American Board of Pathology Hematopathology

Publications & Presentations

PubMed

2 citations
Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy.
Federico Mosna, Erika Borlenghi, Mark Litzow, John C Byrd, Cristina Papayannidis
Haematologica. 2024-10-10
1 citations
KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes.
Bimarzhan Assatova, Robert Willim, Christopher Trevisani, Garrett Haskett, Khyati Maulik Kariya
Clinical Cancer Research. 2024-06-03
1 citations
Optimization of Advanced Molecular Genetic Testing Utilization in Hematopathology: A Goldilocks Approach to Bone Marrow Testing.
Ali AlJabban, Henry Paik, Jon C Aster, Nancy Berliner, Jennifer Brouillard
JCO Oncology Practice. 2024-02-01

Abstracts/Posters

Talazoparib Treatment Preferentially Depletes Cohesin-Mutant Clones in New In Vivo Models of Cohesin-Mutant Myeloid Diseases
Elizabeth A Morgan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

Advanced Cancer Treatment Centers Announces Its Medical StaffSeptember 29th, 2020